group of visiting doctors have assembled for lunch. They’ve come from different places—Birmingham to Dubai—to conduct the Fellowship of the Royal Colleges of Surgeons exam at LV Prasad Eye Institute (LVPEI), which it has been hosting for close to two decades in Hyderabad. After some perfunctory exchanges, the conversation rests on the bow tie. How could it not? The founder of LVPEI, Dr GN Rao, fell for it, discarding the regular silk tie after a glib salesman in New York many years ago sold him the glamour of bowknots. No, not the clip-ons; the self-tie ones. “These doctors will not know how to tie knots, they are not surgeons,” Rao responded in mirth to a Syrian-born, now Dubai-based, ophthalmic surgeon who was also wearing a bow tie. The non-surgeons in the room laughed it away with “We don’t have time for tying knots.”

It doesn’t take Rao much time—less than 15 seconds since he obliged me with a demo—to knot a bow tie. It hasn’t taken him too long either to build one of the largest and finest eye care centres in the world—merely three decades. His network of 163 centres treats about 2 million patients every year, half of whom for free, whatever may be the disease. The absolute numbers in a country of India’s size are always staggering but nothing hits the health index harder than the ill-publicised fact that nearly 60% of eye care in India is in the nonprofit sector.

A few resources-rich individuals have offered him carte blanche to replicate LVPEI in other parts of India. Like this entrepreneur from Mumbai, one of India’s wealthiest persons, who wanted to donate a replica of the Hyderabad centre to his city, which would have cost him nearly Rs 250 crore in an outright donation. Or this young political leader from Delhi who led a ‘diffused group’ of people who wanted an LVPEI in the North. The Board at LVPEI left it to Rao. And Rao said, “Thanks, but no thanks. We can help you but not set it up ourselves because it’ll take away the focus from the care of the neglected population.” To various private equity investors, he says, “We only take one kind of money: donation.”

Expansion on the tech side is, though, welcome. In December 2016, it became one of the partners in Microsoft Intelligent Network for Eyecare (MINE) along with eye care centres in the US, Brazil, Australia and Kenya to use artificial intelligence for eliminating avoidable blindness. A new threat is emerging from modern lifestyle, and doctors believe the world is staring at a myopia epidemic.

I went to Rao, who is 71, arguably India’s most celebrated ophthalmologist today, with some simple questions: Why is eye care concentrated among the nonprofits and why hasn’t this model extended to other therapeutic areas like cardiac, cancer, general medicine…?


Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Available exclusively to subscribers of The Ken India

This story is a part of The Ken India edition. Subscribe. Questions?


Annual Subscription

12-month access to 200+ stories, archive of 800+ stories from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 2,750


Quarterly Subscription

3-month access to 60+ new stories with 3-months worth of archives from our India edition. Plus our premium newsletters, Beyond The First Order and The Nutgraf worth Rs. 99/month or $2/month each for free.

Rs. 1,750


Single Story

Instant access to this story for a year along with comment privileges.

Rs. 500


Annual Subscription

12-month access to 150+ stories from Southeast Asia.

$ 120


Quarterly Subscription

3-month access to 35+ stories from Southeast Asia.

$ 50


Single Story

Instant access to this story for a year along with comment privileges.

$ 20



What is The Ken?

The Ken is a subscription-only business journalism website and app that provides coverage across two editions - India and Southeast Asia.

What kind of stories do you write?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics.

We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

What do I get if I subscribe?

For subscribers of the India edition, we publish a new story every weekday, a premium daily newsletter, Beyond The First Order and a weekly newsletter - The Nutgraf.

For subscribers of the Southeast Asia edition, we publish a new story three days a week and a weekly newsletter, Strait Up.

The annual subscription will get you complete, exclusive access to our archive of previously published stories for your edition, along with access to our subscriber-only mobile apps, our premium comment sections, our newsletter archives and several other gifts and benefits.

Do I need to pay separately for your premium newsletters?

Nope. Paid, premium subscribers of The Ken get our newsletters delivered for free.

Does a subscription to the India edition grant me access to Southeast Asia stories? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

Do you offer an all-access joint subscription for both editions?

Not yet. If you’d like to access both editions, you’ll have to purchase two subscriptions separately - one for India and the other for Southeast Asia.

Do you offer any discounts?

No. We have a zero discounts policy.

Is there a free trial I can opt for?

We don’t offer any trials, but you can sign up for a free account which will give you access to the weekly free story, our archive of free stories and summaries of the paid stories. You can stay on the free account as long as you’d like.

Do you offer refunds?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Please write to us at detailing the error or queries.